Tim Smith

6 days ago | hcplive.com | Tim Smith

New findings support adalimumab biosimilar interchangeability and the practice of non-medical switches between such biosimilars for patients with psoriasis, with the most commonly registered treatment discontinuation reason being a loss of effect.1These findings represent the conclusion of research conducted by such investigators as Ole Krogh-Jensen, from the Department of Dermatology and Allergy at Copenhagen University Hospital in Denmark.

1 week ago | hcplive.com | Tim Smith

Significant psychosocial and occupational burdens are reported by caregivers of adolescents living with alopecia areata, recent findings suggest, as well as mental and emotional well-being impairments.1These data resulted from an analysis by such investigators as Rodney Sinclair, from Sinclair Dermatology in Australia, who noted the value of assessing the effects of alopecia areata on caregiver quality of life for recognizing any unmet needs among such individuals.

1 week ago | hcplive.com | Tim Smith

Positive phase 3 findings on the safety and efficacy of roflumilast foam 0.3% (Zoryve) for those with psoriasis of the scalp and body as a once-daily monotherapy have been published in the Journal of the American Medical Association (JAMA) Dermatology, with results demonstrating rapid and significant relief following treatment.1,2 These data were released on May 7, and they were the conclusion of the phase 3 ARRECTOR study, authored by such investigators as Melinda Gooderham, MD, MSc, medical...

1 week ago | hcplive.com | Tim Smith

New findings point to a possible link between apremilast and interleukin (IL)-17 with a lower incidence of major adverse cardiovascular events (MACE) in patients with psoriasis, whereas cyclosporine showed a higher incidence versus methotrexate.1Juan José Lluch-Galcerá—from the Universitat Autònoma de Barcelona Departament de Medicina in Spain—and a team of other investigators authored the prospective cohort study that led to these findings.

1 week ago | hcplive.com | Tim Smith

Deucravacitinib is an effective and well-tolerated treatment option for patients with moderate to severe plaque psoriasis in Japan, according to recent post-hoc analysis findings, aligning with recent data in the POETYK PSO-4 study.1These results represent the conclusion of new research led by Yukari Okubo, from the Department of Dermatology at Tokyo Medical University in Japan.